Figures & data
Table 1 Patient demographics at baseline
Table 2 Patients in each pain severity category at endpoint
Figure 1 Shift in pain severity category from baseline to endpoint for FM patients.
Notes: Proportion of FM patients with a shift in pain category that was “very much improved” (severe to mild), “much improved” (moderate to mild, or severe to moderate), “no change”, or “worsened” (moderate to severe, mild to moderate, or mild to severe). P=0.013 for pregabalin 300 mg/d versus placebo; P<0.001 for pregabalin 450 mg/d versus placebo; and P=0.138 for pregabalin flex versus placebo.
Abbreviations: flex, flexible dosing; FM, fibromyalgia; d, day.
Abbreviations: flex, flexible dosing; FM, fibromyalgia; d, day.
Figure 2 Shift in pain severity category from baseline to endpoint for DPN/PHN patients.
Notes: Proportion of DPN/PHN patients with a shift in pain category that was “very much improved” (severe to mild), “much improved” (moderate to mild, or severe to moderate), “no change”, or “worsened” (moderate to severe, mild to moderate, or mild to severe). P≤0.001 for each dose of pregabalin versus placebo.
Abbreviations: DPN, diabetic peripheral neuropathy; flex, flexible dosing; PHN, postherpetic neuralgia.
Abbreviations: DPN, diabetic peripheral neuropathy; flex, flexible dosing; PHN, postherpetic neuralgia.
Figure 3 Shift in pain severity category from baseline to endpoint for SCI patients.
Notes: Proportion of SCI patients with a shift in pain category that was “very much improved” (severe to mild), “much improved” (moderate to mild, or severe to moderate), “no change”, or “worsened” (moderate to severe, mild to moderate, or mild to severe). Studies in patients with SCI utilized pregabalin flexible dose only. P=0.010, for pregabalin versus placebo.
Abbreviations: flex, flexible dosing; SCI, spinal cord injury.
Abbreviations: flex, flexible dosing; SCI, spinal cord injury.
